Effect of the two treatments on pregnancy outcome
. | N . | Live births . | P* . | OR . | 95% CI . | P . |
|---|---|---|---|---|---|---|
| All women | < .0001 | |||||
| Aspirin | 80 | 23 (29%) | ||||
| Enoxaparin | 80 | 69 (86%) | 15.5 | 7-34 | < .0001 | |
| AIIFVL | < .0001 | |||||
| Aspirin | 36 | 12 (33%) | ||||
| Enoxaparin | 36 | 34 (94%) | 34 | 7-166 | < .0001 | |
| AIIFIIL | .0007 | |||||
| Aspirin | 30 | 10 (33%) | ||||
| Enoxaparin | 30 | 24 (80%) | 8 | 2.5-26 | .0005 | |
| AIIPS | .0006 | |||||
| Aspirin | 14 | 01 (07%) | ||||
| Enoxaparin | 14 | 11 (79%) | 48 | 4-526 | .0016 |
. | N . | Live births . | P* . | OR . | 95% CI . | P . |
|---|---|---|---|---|---|---|
| All women | < .0001 | |||||
| Aspirin | 80 | 23 (29%) | ||||
| Enoxaparin | 80 | 69 (86%) | 15.5 | 7-34 | < .0001 | |
| AIIFVL | < .0001 | |||||
| Aspirin | 36 | 12 (33%) | ||||
| Enoxaparin | 36 | 34 (94%) | 34 | 7-166 | < .0001 | |
| AIIFIIL | .0007 | |||||
| Aspirin | 30 | 10 (33%) | ||||
| Enoxaparin | 30 | 24 (80%) | 8 | 2.5-26 | .0005 | |
| AIIPS | .0006 | |||||
| Aspirin | 14 | 01 (07%) | ||||
| Enoxaparin | 14 | 11 (79%) | 48 | 4-526 | .0016 |
OR indicates crude odds ratio for giving birth to a live healthy baby after treatment with low-molecular-weight heparin enoxaparin, low-dose aspirin being the treatment of reference; CI, confidence interval; AIIFVL, all patients carrying the heterozygous factor V Leiden mutation; AIIFIIL, all patients carrying the heterozygous factor II G20210A mutation; AIIPS, all patients carrying a protein S deficiency.
Determined by chi-square test.